Overview

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Status:
RECRUITING

Trial end date:
2031-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Treatments:

130-nm albumin-bound paclitaxel
Capecitabine
Paclitaxel